CEO Doug Biehn sits down with Nasdaq’s Leigh Hixon to share Octave’s vision of transforming neurodegenerative disease care through precision medicine. Watch Now

Get in Touch

Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Visualizing the topographical model of multiple sclerosis using novel 3D rendering of quantified MRI

  • Research Presented at ECTRIMS 2024
Download PDF

Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies

  • Research Presented at ECTRIMS 2024
Download PDF

Real-World Utilization of a Multi-Proteomic, Serum-Based Assay for Assessing Response to Therapy in Persons with Multiple Sclerosis

  • Research Presented at ECTRIMS 2024
Download PDF

Safety and effectiveness of cladribine tablets after treatment with natalizumab (CLADRINA trial) – 2 year results

  • Research Presented at ECTRIMS 2024
Download PDF

Impact of MS Imaging Analytics on MRI Report Findings

  • Research Presented at ECTRIMS 2024
Download PDF

Comparing Neuroradiologist Qualitative Rating of Atrophy to Normative Brain Volume Measures

  • Research Presented at CMSC 2024
Download PDF

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS: A Case Study

  • Research Presented at CMSC 2024
Download PDF

Novel Visualization of the Topographical Model of Multiple Sclerosis Using 3D Rendering of Quantified MRI

  • Research Presented at AAN 2024
Download PDF

Predictive Utility of Serum Protein Biomarkers from the Octave MSDA Panel for Optic Neuritis Events in People with Multiple Sclerosis

  • Research Presented at AAN 2024
Download PDF

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

  • Research Presented at ACTRIMS 2024 - February 29 - March 1
Download PDF
1 2 … 9

Visualizing the topographical model of multiple sclerosis using novel 3D rendering of quantified MRI

  • Research Presented at ECTRIMS 2024
Download PDF

Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies

  • Research Presented at ECTRIMS 2024
Download PDF

Real-World Utilization of a Multi-Proteomic, Serum-Based Assay for Assessing Response to Therapy in Persons with Multiple Sclerosis

  • Research Presented at ECTRIMS 2024
Download PDF

Safety and effectiveness of cladribine tablets after treatment with natalizumab (CLADRINA trial) – 2 year results

  • Research Presented at ECTRIMS 2024
Download PDF

Impact of MS Imaging Analytics on MRI Report Findings

  • Research Presented at ECTRIMS 2024
Download PDF

Comparing Neuroradiologist Qualitative Rating of Atrophy to Normative Brain Volume Measures

  • Research Presented at CMSC 2024
Download PDF

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS: A Case Study

  • Research Presented at CMSC 2024
Download PDF

Novel Visualization of the Topographical Model of Multiple Sclerosis Using 3D Rendering of Quantified MRI

  • Research Presented at AAN 2024
Download PDF

Predictive Utility of Serum Protein Biomarkers from the Octave MSDA Panel for Optic Neuritis Events in People with Multiple Sclerosis

  • Research Presented at AAN 2024
Download PDF

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

  • Research Presented at ACTRIMS 2024 - February 29 - March 1
Download PDF
Load More

© 2024 Octave Bioscience, Inc | 1440 O’Brien Drive, Suite B, Menlo Park, CA 94025 

Connect with us